[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Annexon, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100594543","phase-3-an-open-label-clinical-study-to-evaluate-tanruprubart-also-commonly-known-as-anx005-in-participants-with-guillain-barr-syndrome-forward-study-100594543",false,"NCT07020819","An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)","An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (GBS) (FORWARD Study)","Key Inclusion Criteria:\n\n* Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for GBS.\n* Onset of GBS-related weakness ≤10 days before start of infusion on Day 1\n* GBS-disability score (DS) score of 3, 4, or 5 at screening and before start of infusion on Day 1.\n\nKey Exclusion Criteria:\n\n* Previous or intended treatment with either plasma exchange or IV immunoglobulin for GBS.\n* Diagnosis of a variant of GBS, including Miller Fisher syndrome, Bickerstaff's encephalitis, and overlap syndromes.\n\nOther protocol-defined criteria may apply.","ALL","12 Years","85 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.",[27],"Guillain-Barre Syndrome",[27,29,30,31,32],"GBS","ANX005","Tanruprubart","FORWARD study","RECRUITING","2026-05-27",{"date":36,"type":37},"2026-05-28","ACTUAL",{"date":39,"type":37},"2025-09-12",{"date":41,"type":21},"2028-06-30",{"name":43,"class":44},"Annexon, Inc.","INDUSTRY",13,""]